May 20, 2025 4:47pm

Share pricing slides, as algos and electronic trading “thirst” after multiple positive “plays

As I had wrote Monday, “Many cell and gene therapy sector equities were lying in the weeds at the open, then flying; let’s NOT be too optimistic to buying dips and hanging on to highs”

News: REGENXBIO (RGNX +$0.21 or +2.15% to $10.00) closed a non-dilutive, limited recourse royalty bond agreement of up to $250 M with Healthcare Royalty (HCRx). This agreement monetizes select anticipated royalties and milestones, and provides both immediate and expected future, non-dilutive capital.  RGNX received $150 M at closing, extending the cash runway into 1H/2027.

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets.

I put hours of effort to create reporting, while leveraging my 40 years of operating. investigative and research experiences to analyze the key market-moving events and distill that into a cogent outlook.

 

Monday’s RegMed Investors’ (RMi) pre-open: what’s the ante today? … https://www.regmedinvestors.com/articles/13926

Friday night’s RegMed Investors (RMi) Closing Bell: Slippin’ then flippin to the upside… https://www.regmedinvestors.com/articles/13925

 

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN) Chronicles: Yet another "screw job" for/on investors ... "wanting to effect a reverse split of its outstanding common stock" in its recent proxy statement filing!! … https://www.regmedinvestors.com/articles/13812

 

Tuesday: The Dow closed DOWN -114.83 points or -0.27%, the S&P closed DOWN -23.14 points or -0.39% while the Nasdaq closed DOWN -72.75 points or -0.38%

  • Indexes tripped to the downside negative after closing positive on Monday following Moody’s downgrade of the U.S. credit rating late Friday, causing Treasury yields to spike.

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

 

  • Moderna (MRNA +8.8%) and Pfizer (PFE +1.9%) shares rose Tuesday after the FDA gave new regulatory guidance for future Covid-19 vaccine boosters, which sets stricter approval standards for healthy Americans. The FDA recommended different standards of evidence for approval based on patients’ risk of getting severely sick from Covid. <the New England Journal of Medicine>

Tuesday’s advance/decline line opened with a negative 15 incliner, 18 decline and 2 flats ending with a posiive close of 23 incliners, 9 decliners and 3 flat      

Metrics:  Tuesday, the IBB was up +2.16%, the XBI was up +1.69% while the VIX was down -0.04 points or -0.22% at 18.09

 

Q2/25 – May – 6 negative and 8 positive closes

  • April – 11 positive and 10 negative closes

Q1/25

  • March, 10 positive and 12 negative closes
  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Tuesdays Closing UP (10 of 23) +$ after Monday’s

  • Blueprint Medicine (BPMC +$1.79 after Monday’s -$0.48 after Friday’s +$2.20
  • Moderna (MRNA +$1.60 after Monday’s +$1.53 after Friday’s +$1.21),
  • Ultragenyx Pharmaceuticals (RARE +$1.16 after Monday’s +$0.58 after Friday’s +$0.77),
  • Vericel (VCEL +$0.98),
  • Intellia Therapeutics (NTLA +$0.61 after Monday’s +$0.56),
  • uniQure NV (QURE +$0.60 after Monday’s +$1.01 after Friday’s +$0.45),
  • CRISPR Therapeutics (CRSP +$0.57 after Monday’s -$0.09 after Friday’s +$2.46
  • Ionis Pharmaceuticals (IONS +$0.44 after Monday’s +$0.47 after Friday’s +$0.57),
  • Adverum Biotechnologies (ADVM +$0.29),
  • Lenz Therapeutics (LENZ +$0.28 after Monday’s +$1.64 after Friday’s -$0.53),

Flat (3)

  • bluebird bio (BLUE,
  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Monday’s -$0.14 after Friday’s $0.00
  • Homology Medicine (FIXX)

Tuesday’s Closing DOWN (9 of 9): 

  • AxoGen (AXGN -$0.19 after Monday’s -$0.07),
  • Alnylam Pharmaceuticals (ALNY -$0.18 after Monday’s +$6.67 after Friday’s +$1.91),
  • Prime Medicine (PRME -$0.16 after Monday’s -$0.25),
  • BioLife Solutions (BLFS -$0.13 after Monday’s -$0.65 after Friday’s +$1.60
  • Brainstorm Cell Therapeutics (BCLI -$0.12),
  • Cellectis SA (CLLS -$0.0399 after Monday’s -$0.02),
  • Voyager Therapeutics (VYGR -$0.03)
  • Mesoblast (MESO -$0.01 after Monday’s -$0.17 after Friday’s -$0.23),
  • Compass Therapeutics (CMPX -$0.01),

 

The BOTTOM LINE: Tuesday’s session slipped after Moody’s tried or … has … spooked markets.

  • Indexes slid on Tuesday, pulling back from their recent rally amid growing warnings that investor relief over a cooling in trade tensions and in US inflation may be misplaced.

While markets initially brushed off the downgrade,  warn ... the bond market isn't out of the woods yet as fiscal uncertainty and persistent inflation pressures will likely fuel further turbulence in long-run Treasurys.

  • Some … “Investors should lean into equities in a 'glass half full' market”

What more can be written, another surprise upside …

May ‘25: understand the “flow” …

  • 5/20 – Tuesday closed positive with 23 positive, 9 negative and 3 flats
  • 5/19 – Monday closed positive with 23 positive, 12 negative and 1 flat\
  • 5/16 - Friday closed positive with 29 positive, 3 negative and 3 flats
  • 5/15 – Thursday closed positive with 24 positive, 10 negative and 1 flat
  • 5/14 – Wednesday closed negative with 8 positive, 25 negative and 2 flats
  • 5/13 – Tuesday closed negative with 6 positive, 28 negative and 1 flat
  • 5/12 - Monday positive with 39 positive, 3 negative and 2 flats
  • 5/9 - Friday closed negative with 10 positive, 23 negative and 2 flats
  • 5/8 – Thursday closed positive with 25 positive, 8 negative and 2 flats
  • 5/7 - Wednesday closed positive with 16 positive, 15 negative and 4 flats
  • 5/6 – Tuesday closed negative with 2 positive, 31 negative and 2 flats
  • 5/5 - Monday closed negative with 9 positive, 23 negative and 3 flats
  • 5/2 – Friday closed positive with 24 positive, 8 negative and 3 flats
  • 5/1 - Thursday closed negative with 14 positive, 19 negative and 2 flats

 

I usually write/say “electronic trading and uncle algo” slips in and out, back doors reaping sector disharmony and then pops right back for some profiteering.

  • What can I say, love ‘em, leave ‘em and welcome back to save the sector’s honor – “uncle algo and his electronic dwarfs.” <me>

My perspective is retail investors should NOT be dipping their toes back into the cell and gene therapy sector until after LPS (loss-per-share) earnings report.

  • NO all ins – just add those with solid partners, lengthened runways and solid cash positions leveraged by solid management teams – there I see losses going forward!

Market news i.e., tariff drive upside yet estimate and consensus misses with continued earnings LPS (loss-per-share) will shake the sector down – the vig must be paid!

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Tuesday: Blueprint Medicine (BPMC), Moderna (MRNA) and Ultragenyx Pharmaceuticals (RARE)
  • Monday: Alnylam Pharmaceuticals (ALNY), Lenz Therapeutics (LENZ) and Moderna (MRNA)
  • Friday: CRISPR Therapeutics (CRSP), Blueprint Medicine (BPMC) and Alnylam Pharmaceuticals (ALNY)

The worst three (3) in the session: 

  • Tuesday: AxoGen (AXGN), Alnylam Pharmaceuticals (ALNY) and Prime medicine (PRME)
  • Monday: BioLife Solutions (BLFS), Blueprint Medicine (BPMC) and Verve therapeutics (VERV)
  • Friday: Lenz Therapeutics (LENZ), Mesoblast (MESO) and MiMedx (MDXG)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.